Baxter begins Phase II trials of endovascular AAA (abdominal aortic aneurysm) treatment following rivals Medtronic and Guidant
This article was originally published in Clinica
Executive Summary
Another endovascular treatment for abdominal aortic aneurysms (AAAs) has entered trials in the US. Phase II studies of Baxter CardioVascular's Lifepath device have been approved by the FDA and around 150 patients will be treated.